Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Files An 8-K Entry into a Material Definitive AgreementItem 1.01.Entry into a Material Definitive Agreement.
Third and Fourth Supplements to Exclusive License and Supply Agreement
On December 24, 2009, Reata Pharmaceuticals, Inc. (the “Company”) previously entered into the Exclusive License and Supply Agreement (the “Original License Agreement”) by and between the Company and Kyowa Hakko Kirin Co., Ltd. (“KHK”) under which the Company provided KHK the right to develop and commercialize bardoxolone methyl for renal, metabolic, and cardiovascular indications in Japan, China (including Hong Kong and Macao), South Korea, Taiwan, Thailand, Singapore, Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia.
On December 7, 2017, the Company entered into the Third Supplement to Exclusive License and Supply Agreement (the “Third Supplement”), by and between the Company and KHK. The Third Supplement allows the Company to begin a portion of a Phase 3 clinical study of RTA 402 (which is a licensed compound) in the field of Alport syndrome in the country of Japan.
On December 7, 2017, the Company entered into the Fourth Supplement to Exclusive License and Supply Agreement (the “Fourth Supplement”), by and between the Company and KHK. The Fourth Supplement further amends the original agreement between the Company and KHK by revising various pricing terms and payments between the parties.
The foregoing descriptions of the Original License Agreement, the Third Supplement and the Fourth Supplement are qualified in their entirety by reference to the full text of the Original License, Agreement, the Third Supplement and the Fourth Supplement, as applicable. The Original License Agreement is attached as Exhibit 10.15 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. The Third Supplement and the Fourth Supplement are attached as Exhibit 10.1 and Exhibit 10.2 to this Current Report on Form 8-K and incorporated in this Item 1.01 by reference.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits
|
ExhibitNo. |
Description |
|
10.1* |
Third Supplement to Exclusive License and Supply Agreement, dated as of December 6, 2017, between Reata Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd. |
|
10.2* |
Fourth Supplement to Exclusive License and Supply Agreement, dated as of December 6, 2017, between Reata Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd. |
|
* Confidential information has been omitted from this Exhibit and has been filed separately with the Securities and Exchange Commission to a confidential treatment request under Rule 24b-2of the Securities and Exchange Commission Act of 1934. |
REATA PHARMACEUTICALS INC ExhibitEX-10.1 2 reta-ex101_29.htm EX-10.1 reta-ex101_29.htm Exhibit 10.1 THIRD SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Phase 3 Clinical Study (Alport Syndrome) in Japan This Third Supplement (herein so called),…To view the full exhibit click here
About Reata Pharmaceuticals, Inc. (NASDAQ:RETA)
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company’s lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich’s ataxia, mitochondrial myopathies and metastatic melanoma.